3C PATCH® REIMBURSEMENT

3C Patch® System is an FDA-cleared advanced wound management solution

Currently covered by CMS in all 50 States in the US

Medicare Code – G0460

Ambulatory Payment Classification – 5054

National Average Payment – $1.622.74

Nurse inputting data into a computer

FOR MORE INFORMATION AND PRODUCT PRICING

Scientific and clinical data support the effect of 3C Patch® in wound management, compared to standard of care.

The results of a multinational, multicentre randomized clinical trial published in Lancet Diabetes & Endocrinology 2018 served as the basis for CMS reimbursement.
The International Working Group on Diabetic Foot recommends 3C Patch® as adjunctive therapy for hard-to-heal diabetic foot ulcers.
Our reimbursement specialists are available to provide support and answer any questions you might have about coding, billing, and reimbursement. Give us a call or send us an email and we will be happy to assist you.

FDA CLEARANCE

The 3C Patch® System is cleared by the FDA for the management of exuding wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically debrided wounds.

CE MARKED IN EUROPE

The intended use of the 3C Patch® Device is to produce an autologous platelet-rich fibrin for wound management of recalcitrant wounds.